Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

EUROPE MARKETS: European Stocks Gain, But AstraZeneca Slumps

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/27/2014 | 06:19pm CET

By Carla Mozee, MarketWatch

LONDON (MarketWatch) -- European stocks advanced Tuesday, with the pan-European benchmark hanging at a six-year high, but AstraZeneca PLC shares were stuck in the red after Pfizer Inc. officially walked away from its pursuit of the British drug maker.

The Stoxx Europe 600 index closed up 0.2% at 344.47 after a 0.6% run higher on Monday following European parliamentary elections.

European markets were additionally buoyed by "further dovish remarks" by European Central Bank President Draghi who "highlighted the risk of a negative spiral between low inflation, falling inflation expectations and credit for the euro area," said Guillermo Felices at Barclays asset allocation research, in a note Tuesday. "We retain our call that the ECB will cut its policy rate and/or announce targeted liquidity measures to support bank lending," at the Governing Council's meeting on June 5.

On Tuesday, Belgium, the first euro-zone country to report inflation data for May, said growth in consumer prices dropped to the lowest level in more than four years, with an inflation rate of 0.36%. The Belgium BEL 20 stock index rose 0.3% to 3,153.97.

There were strong gains in the European parliamentary elections, which ended Sunday, for anti-European Union and far-right parties, reflecting widespread voter frustration over economic austerity and lackluster growth. Overall, centrist, pro-European parties are poised to hold a majority of the 751 seats in the legislature.

Investors "took the electoral success in stride. The duopoly of the center-right and center-left will persist and still dominate the EU parliament," said currency analysts at Brown Brothers Harriman in a report Tuesday. "This will likely become clearer when the new [European Commission] president and commission are put together," they said. "The anti-EU vote is far from a unitary bloc. They are a disparate collection of national parties."

Germany's DAX 30 index turned higher by 0.5% to 9,940.82, and France's CAC 40 index moved up 0.1% to 4,529.75.

Aveva Group surged 8.8%, the best performer on the Stoxx 600, after the British engineering data and design IT systems company posted a 9% rise in 2014 pretax profit.

Trading resumed in the U.K. after Monday's Bank holiday. The FTSE 100 rose 0.4% to 6,844.94, led by InterContinental Hotels Group . Its shares climbed 3.1% after the owner of Holiday Inns, Crowe Plaza and other hospitality chains reportedly said over the weekend it rejected a GBP6 billion bid ($10.12 billion) from an unnamed U.S. company.

But AstraZeneca PLC (>> AstraZeneca plc) dropped 1.8% after Pfizer Inc. (>> Pfizer Inc.) officially walked away from its offer to buy the British drug maker for $120 billion.

The increased bid came four weeks from the confirmation of Pfizer's first offer, which was also rejected by AstraZeneca. U.K. takeover rules gave the firms until Monday to enter takeover discussions. Société Générale cut its rating on AstraZeneca to sell from hold, and Panmure Gordon lowered its price target on the company, according to Dow Jones Newswires.

Meanwhile, Russian stocks were knocked lower as dozens of pro-Russian separatists were killed by Ukrainian forces in heavy fighting at Donetsk International Airport. On Sunday, pro-Europe chocolate baron Petro Poroshenko was elected as Ukraine's new president. The blue-chips MICEX index fell 2.5%, and the RTS index gave up 2.9%.

The political crisis in Ukraine slashed Russian lender VTB Bank's first-quarter profit by 98% to 400 million rubles ($11.7 million).

Italy's FTSE MIB index tilted lower by 0.4% to 21,403.55 after swinging between gains and losses. The index had been higher following a report that consumer confidence in the country in May rose to its highest level since January 2010.The MIB index on Monday rallied 1.8%, led by bank stocks, after Italian Prime Minister Matteo Renzi's center-left Democratic Party defeated a challenge from a euroskeptic party headed by comedian Beppe Grillo.

More must-reads from MarketWatch:

Belgian data is bad omen for the euro zone

Dividend-yielding stocks are paying off now

To beat insomnia, say good night to this first

Stocks mentioned in the article : AstraZeneca plc, Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
10:16a ASTRAZENECA : AZ says 5R framework increased R&D productivity
01/20 ASTRAZENECA : boasts of quadrupling of R&D productivity at biotech unit
01/20 ASTRAZENECA : scores double approvals in Japan for asthma and ovarian cancer
01/20 ASTRAZENECA : X-Chem Enters Expanded Global Drug Discovery And Technology Transf..
01/19 FINDINGS FROM ASTRAZENECA BROADEN UN : ...
01/19 ASTRAZENECA : 0.1% Potential Decrease Indicated by Liberum Capital
01/19 ASTRAZENECA : X-Chem collaborates with AstraZeneca
01/19 ASTRAZENECA : Lynparza receives approval in Japan for the treatment of advanced ..
01/19 ASTRAZENECA : Fasenra receives approval in Japan
01/19 ASTRAZENECA : Reports from AstraZeneca Add New Data to Findings in DNA Research ..
More news
News from SeekingAlpha
01:23a BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Novartis's Speedy Review, Aeterna's Surpr..
01/21 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 20, 2018
01/20 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O..
01/19 AstraZeneca's Lynparza OK'd in Japan for ovarian cancer; shares up 1% premark..
01/18 ARMO BioSciences Proposes Terms For $100 U.S. IPO
Financials ($)
Sales 2017 21 851 M
EBIT 2017 5 694 M
Net income 2017 2 297 M
Debt 2017 12 304 M
Yield 2017 3,92%
P/E ratio 2017 35,64
P/E ratio 2018 30,52
EV / Sales 2017 4,61x
EV / Sales 2018 4,60x
Capitalization 88 434 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 69,1 $
Spread / Average Target -1,1%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-1.52%88 702
JOHNSON & JOHNSON5.47%395 886
NOVARTIS1.19%227 592
PFIZER1.99%220 189
ROCHE HOLDING LTD.-4.87%211 135
MERCK AND COMPANY8.90%167 132